Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world.

A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in both plasma and other biopharmaceuticals to enhance quality of life.

Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, we have the largest network of donation centers in the world, with more than 400 centers across North America, Europe, Africa and the Middle East, and in China through a partnership with Shanghai RAAS.

We are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.